The long-term course of panic disorder and its predictors

Journal of Clinical Psychopharmacology

Volumn 18, Issue 6 SUPPL. 2, 1998, Pages

  Katschnig, Heinz ^a   Amering, Michaela ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AGORAPHOBIA; CONFERENCE PAPER; DEPRESSION; FOLLOW UP; HUMAN; OUTCOMES RESEARCH; PANIC; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION;

EID: 0031758354     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199812001-00003     Document Type: Conference Paper

References (37)

1. Drug treatment of panic disorder comparative efficacy of alprazolam, imipramine and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. Br J Psychiatry 1992; 160:191-202.
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler K. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity study. Arch Gen Psychiatry 1994;51:8-19.
3. Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States. Am J Psychiatry 1994;151:413-20.
4. Regier DA, Boyd JH, Burke JD Jr, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Locke BZ. One-month prevalence of mental disorders in the United States. Arch Gen Psychiatry 1988;45:977-86.
5. Eaton WW, Dryman A, Weissman MM. Panic and phobia: the diagnosis of panic disorder and phobic disorder. In: Robins LN, Regier DA, eds. Psychiatric disorders in America: the epidemiologic catchment area study. New York: The Free Press, 1991: 155-79.
6. Weissman MM. The epidemiology of panic disorder and agoraphobia. In: Frances AJ, Hales RE, eds. American Psychiatric Press review of psychiatry. Vol 7. Washington, DC: American Psychiatric Press, Inc., 1988:54-66.
7. Klerman GL, Weissman MM, Ouellette R, Johnson J, Greenwald S. Panic attacks in the community: social morbidity and health care utilization. JAMA 1991;265:742-6.
8. Katschnig H, Amering M. The long-term course of panic disorder. In: Wolf BE, Maser JD, eds. Treatment of panic disorder: a consensus development conference. Washington, DC: American Psychiatric Press, Inc., 1994:196-206.
9. Roy-Byrne PP, Cowley DS. Course and outcome in panic disorder: a review of recent follow-up studies. Anxiety 1995;1:151-60.
10. Katschnig H, Amering M, Stolk JM, Klerman GL, Ballenger JC, Briggs A, Buller R, Cassano G, Garvey M, Roth M, Solyom C. Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry 1995;167:487-94.
11. Shear MK, Maser JD. Standardized assessment for panic disorder research: a conference report. Arch Gen Psychiatry 1994;51: 346-54
12. Starcevic V. Treatment goals for panic disorder. J Clin Psychopharmacol 1998;18[suppl 2];19S-26S.
13. Marks I, Lader M. Anxiety states (anxiety neurosis): a review. J Nerv Ment Dis 1973;156:3-18.
14. Craske MG, Brown TA, Barlow DH. Behavioral treatment of panic disorder: a two-year follow-up. Behav Ther 1991;22:289-304.
15. Beck AT, Sokol L, Clark DA, Berchick R, Wright F. A crossover study of focused cognitive therapy for panic disorder. Am J Psychiatry 1992;149:778-83.
16. Nagy LM, Krystal JH, Charney DS, Merikangas KR, Woods SW. Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study. J Clin Psychopharmacol 1993;13:16-24.
17. Vollrath M, Angst J. Outcome of panic and depression in a seven-year follow-up: results of the Zurich study. Acta Psychiatr Scand 1989;80:591-6.
18. Lelliott PT, Marks IM, Monteiro WO, Tsakiris F, Noshirvani H. Agoraphobics 5 years after imipramine and exposure. J Nerv Ment Dis 1987;175:599-605.
19. Mavissakalian M, Michelson L. Two-year follow-up of exposure and imipramine treatment of agoraphobia. Am J Psychiatry 1986; 143:1106-12.
20. Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and medication outcome after short-term alprazolam and behaviorial group treatment in panic disorder. Arch Gen Psychiatry 1989;46: 993-9
21. Lepola UM, Rimón RH, Riekkinen PJ. Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. Int Clin Psychopharmacol 1993; 8:115-8.
22. Albus M, Scheibe G. Outcome of panic disorder with or without concomitant depression: a 2-year prospective follow-up study. Am J Psychiatry 1993;150:1878-80.
23. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993;13:257-63.
24. Faravelli C, Albanesi G. Agoraphobia with panic attacks: 1-year prospective follow-up. Compr Psychiatry 1987;28:481-7.
25. Maier W, Buller R. One-year follow-up of panic disorder. Eur Arch Psychiatry Neurol Sci 1988;238:105-9.
26. Noyes R Jr, Clancy J, Woodman C, Holt CS, Suelzer M, Christiansen J, Anderson D. Environmental factors related to the outcome of panic disorder: a seven-year follow-up study. J Nerv Ment Dis 1993;181:529-38.
27. Noyes R Jr, Reich J, Christiansen J, Suelzer M, Pfohl B, Coryell A. Outcome of panic disorder: relationship to diagnostic subtypes and comorbidity. Arch Gen Psychiatry 1990;47:809-18.
28. Noyes R, Garvey MJ, Cook BL. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Dis 1989;16:249-57.
29. Keller MB, Yonkers KA, Warshaw MG, Pratt LA, Gollan JK, Massion AO, White K, Swartz AR, Reich J, Lavori PW. Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up. J Nerv Ment Dis 1994;182:290-6.
30. Cowley DS, Flick SN, Roy-Byrne PP. Long-term course and outcome in panic disorder, a naturalistic follow-up study. Anxiety 1996;2:13-21.
31. Zubin J, Spring B. Vulnerability a new view of schizophrenia J Abnorm Psych 1977;86:103-26.
32. Strauss JS, Hafez H, Liebermann P, Harding CM. The course of psychiatric disorders. III. Longitudinal principles. Am J Psychiatry 1985;142:289-96.
33. Telch MJ, Agras WS, Taylor CB, Roth WT, Gallen CC. Combined pharmacological and behavioral treatment for agoraphobia Behav Res Ther 1985;23:325-35.
34. Mavissakalian M. The mutually potentiating effects of imipramine and exposure in agoraphobia. In: Hand I, Wittchen HU, eds. Panic and phobias. Berlin: Springer, 1988.
35. O'Rourke D, Fahy TJ, Brophy J, Prescott P. The Galway Study of Panic Disorder. III. Outcome at 5 to 6 years. Br J Psychiatry 1996;168:462-9.
36. Warshaw MG, Massion AO, Shea MT, Allsworth J, Keller MB. Predictors of remission in patients with panic with and without agoraphobia prospective 5-year follow-up data [brief report]. J Nerv Ment Dis 1997;185:517-9.
37. Katschnig H, Amering M, Stolk JM, Ballenger JC. Predictors of quality of life in a long-term follow-up study in panic disorder patients after a clinical drug trial Psychopharmacol Bull 1996;32:149-55.